Abstract: An aptamer specific to ovarian cancer and a detection method for ovarian cancer are provided. The aptamer includes a following nucleotide sequence: 5?-ncaaannncnnnnanncnnnnnnnnnnngaannnannngg-3?, wherein n is a nucleotide independently selected from “a,” “t,” “c,” and “g.

Abstract: The present disclosure relates to an oligopeptide which is highly specific to an ovarian cancer. The oligopeptide includes an amino acid sequence of SEQ ID NO: 1. The present disclosure also relates to a test kit including the oligopeptide for detecting ovarian cancer and an ovarian cancer detection method by using the oligopeptide.

Abstract: An aptamer specific to ovarian cancer and a detection method for ovarian cancer are provided. The aptamer includes a following nucleotide sequence: 5?-ncaaannncnnnnanncnnnimnnnnngaannnannngg-3?, wherein n is a nucleotide independently selected from “a,” “t,” “c,” and “g.

Abstract: A microfluidic in-vitro screening chip system including a first micromixer chamber, a plurality of first storage chambers, a second micromixer chamber and a plurality of second storage chambers. The first micromixer chamber includes a non-target disease tissue slide region. The plurality of first storage chambers are connected to the first micromixer chamber, wherein at least one first storage chamber is used for storing a library. The second micromixer chamber is connected to the first micromixer chamber, and the second micromixer chamber includes a target disease tissue slide region. The plurality of second storage chambers are connected to the second micromixer chamber.

Abstract: The present disclosure relates to an oligopeptide which is highly specific to an ovarian cancer. The oligopeptide includes an amino acid sequence of SEQ ID NO: 1. The present disclosure also relates to a test kit including the oligopeptide for detecting ovarian cancer and an ovarian cancer detection method by using the oligopeptide.

Abstract: The present invention provides ovarian cancer-specific aptamers, which are selected in vitro using SELEX and a microfluidic chip system. The aptamers can also bind to different histologically-classified ovarian cancer cells with high affinity accordingly. Therefore, the aptamers of the present invention and the applications thereof can not only be used in detection of ovarian cancer cells but also be applied in recognition of different histologically-classified ovarian cancer cells.

Abstract: The present invention provides an oligopeptide specific to colorectal cancer cells, which are selected from a group of peptide sequences consisting of Seq ID: NO. 1 to Seq ID: NO. 3.

Abstract: The present invention provides an oligopeptide specific to colorectal cancer cells, which are selected from a group of peptide sequences consisting of Seq ID: NO. 1 to Seq ID: NO. 3.

Abstract: The present invention provides an aptamer specific to colorectal cancer cells and comprises a nucleotide sequence selected from the group consisting of Seq ID: NO. 1 to Seq ID: NO. 14. The aptamer of the present invention specific to colorectal cancer cell may be applied in colorectal cancer detection and provide a detection method having non-invasive, fast and convenient properties.

Abstract: The present invention provides ovarian cancer-specific aptamers, which are selected in vitro using SELEX and a microfluidic chip system. The aptamers can also bind to different histologically-classified ovarian cancer cells with high affinity accordingly. Therefore, the aptamers of the present invention and the applications thereof can not only be used in detection of ovarian cancer cells but also be applied in recognition of different histologically-classified ovarian cancer cells.